Kenya pharmacy PrEP trial: a new way to fight HIV?

NCT ID NCT05842122

Completed Prevention Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether providing HIV prevention pills (PrEP and PEP) at local pharmacies in Kenya helps more people start and continue taking them, compared to the usual clinic referral. Over 5,800 participants from 60 pharmacies were involved. The goal was to see if pharmacy-based delivery, with a small fee, improves access and adherence to these life-saving medications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PrEP (pre-exposure prophylaxis) and PEP (post-exposure prophylaxis) medications
What this could lead to: If successful, this model could make HIV prevention pills more accessible and convenient, potentially reducing new HIV infections in Kenya and similar settings.
What could go wrong: This is a completed trial, but results may not apply to other countries or populations. The intervention relies on pharmacy staff training and client willingness to pay a small fee, which could limit uptake.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

Kenya Medical Research Institute

Kisumu, Kenya
Partners in Health & Research Development

Thika, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.